Top line accelerating.
+15.6% YoY versus +11.3% prior. 3y CAGR +17.0%.
+15.6%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
The Question
2 of 3 legendary models say BUY DXCM — but Charlie Munger disagrees.
What would legendary investors pay for DXCM?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
Yes — DexCom, Inc.'s 30.5% ROE ranks above the S&P 500 median, and D/E 1.31 stays within healthy bounds.
Financial story
Yes — DexCom, Inc.'s 30.5% ROE shows strong capital efficiency, and its 1.31 debt-to-equity stays within healthy bounds.
Bottom line: DXCM is rated BUY by 2 of 3 legendary models, with 0 holding and 1 flagging it overvalued, but earns a C sector grade (58/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
+15.6% YoY versus +11.3% prior. 3y CAGR +17.0%.
+15.6%Net margin 17.9% versus 14.3% prior (+3.7pp). Operating 19.6%.
17.9%P/E 31.1x — 51% below the 5y median of 62.9x. Forward 28.0x hints at EPS expansion next year.
31.1xDXCM and VEEV differ on P/E, ROE, and revenue growth. See the full DXCM vs VEEV compare matrix.
Buffett, Lynch, and Munger evaluate DXCM against their respective frameworks. Per-model fair value and reasoning are in the valuation tab.
DXCM's P/E ratio is 29.8x. 5-year P/E history is in the financials tab.
2 of 3 legendary models say BUY. Full breakdown by investor and signal is in the valuation tab.
DXCM's earnings calendar and history are tracked in the financials tab. Specific dates depend on company-published guidance.
DXCM is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
How does DXCM compare?
See exactly where DXCM ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingDXCM sits at #21 in Healthcare with a C grade (58/100).